Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin?s lymphoma: in combination with the International Prognostic Index

Goto, Hideko; Tsurumi, Hisashi; Takemura, Masao; Ino-Shimomura, Yoriko; Kasahara, Senji; Sawada, Michio; Yamada, Toshiki; Hara, Takeshi; Fukuno, Kenji; Goto, Naoe; Okuno, Masataka; Takami, Taro; Seishima, Mitsuru; Moriwaki, Hisataka

doi:10.1007/s00432-004-0600-9

Cited by 58 publications

(41 citation statements)

References 34 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It might not be commonly used in North America and Europe, although it has been reported that the elevated serum levels of sIL-2R have correlated with poor prognoses in a number of different types of lymphoid malignancies, particularly B-cell lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma. [27][28][29][30] In Japan, it is included in the current routine practice of examinations for patients with lymphoma. The soluble form of IL-2R is naturally released by proteolytic shedding from activated T cells.…”

Section: Discussionmentioning

confidence: 99%

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma

Katsuya

Shimokawa

Ishitsuka

et al. 2017

Blood

View full text Add to dashboard Cite

Key Points• The soluble interleukin-2 receptor was identified as an only independent prognostic factor for chronic and smoldering ATL in this study.• The prognostic index using the values of sIL-2R (iATL-PI) is a promising tool for the risk-adapted therapeutic intervention.Adult T-cell leukemia-lymphoma (ATL) has been divided into 4 clinical subtypes: acute, lymphoma, chronic, and smoldering. The aim of this study is to develop a novel prognostic index (PI) for chronic and smoldering ATL. We conducted a nationwide retrospective survey on ATL patients, and 248 fully eligible individuals were used in this analysis. In the univariate analysis, sex, performance status, log 10 (soluble interleukin-2 receptor [sIL-2R]), neutrophils count, and lymphadenopathy showed values of P < .05 in training samples. A multivariate analysis was performed on these factors, and only log 10

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma

Katsuya

Shimokawa

Ishitsuka

et al. 2017

Blood

View full text Add to dashboard Cite

show abstract

“…Therefore, circulating sCD25 level is considered as an indicator of the immune inhibition degree (Goto et al, 2005). Bien and Balcerska (Bien and Balcerska, 2008) suggest that in most patients with haematological malignancies, tumor cells continuously producing a large number of sCD25 is the main reason for the upregulation of sCD25.…”

Section: Discussionmentioning

confidence: 99%

Epirubicin Inhibits Soluble CD25 Secretion by Treg Cells Isolated from Diffuse Large B-cell Lymphoma Patients

Wang

Liu

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…High serum levels of the soluble form of CD25 (sCD25) have been associated with increased tumor activity, tumor aggressiveness, and also poor prognosis, mainly in human lymphoproliferative neoplasms but also in renal cell cancer and melanoma. 9,17,30 Furthermore, de novo CD25 expression was found on neoplastic lymphoid cells and to a lesser extent on nonlymphoid cancer cells such as melanoma and several carcinomas, but again, the function and impact on tumor development and behavior have not been clarified. 1,3,12,14,33,40,45 Apart from its potential role as a pro-proliferative factor, CD25 could also function as a modulator of immune-mediated tumor response.…”

Section: Discussionmentioning

confidence: 99%

CD25 Is Expressed by Canine Cutaneous Mast Cell Tumors but not by Cutaneous Connective Tissue Mast Cells

2012

View full text Add to dashboard Cite

Canine cutaneous mast cell tumors (MCT) of different histological grades have distinct biological behaviors. However, little is known about underlying molecular mechanisms that lead to tumor development and increasing malignancy with higher tumor grade. Recent studies have identified the interleukin-2 receptor (IL-2R) subunits CD25 and CD2 as markers that distinguish nonneoplastic from neoplastic mast cells in human systemic mastocytosis. In this study, their potential as a marker for canine MCT and their possible impact on MCT carcinogenesis were evaluated. mRNA expression levels of both genes were compared between grade 1 ( n = 12) and grade 3 ( n = 8) MCT, and protein expression levels of CD25 were compared in 90 MCT of different tumor grades. mRNA expression levels of both CD25 and CD2 were upregulated in grade 3 MCT. In contrast, CD25 protein was expressed by fewer tumor cells and at decreased levels in grade 3 tumors, while most grade 1 MCT had strong CD25 protein expression. Moreover, CD25 was not expressed by nonneoplastic, resting cutaneous mast cells, while few presumably activated mast cells in tissue samples from dogs with allergic dermatitis had weak CD25 expression. Taken together, these findings suggest that CD25 may play a critical role in early MCT development and may be a stimulatory factor in grade 1 MCT, while grade 3 MCT seem to be less dependent on CD25. Because of the low number of CD25-positive tumor cells in high-grade tumors, the usefulness of CD25 as a tumor marker is, however, questionable.

show abstract

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin?s lymphoma: in combination with the International Prognostic Index

Abstract: The results suggest that a high serum sIL-2R level predicts a poor prognosis in aggressive NHL and may be a useful biomarker for selecting appropriate treatment when used in combination with the IPI.

Cited by 58 publications

References 34 publications

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma

Epirubicin Inhibits Soluble CD25 Secretion by Treg Cells Isolated from Diffuse Large B-cell Lymphoma Patients

CD25 Is Expressed by Canine Cutaneous Mast Cell Tumors but not by Cutaneous Connective Tissue Mast Cells

Contact Info

Product

Resources

About